[go: up one dir, main page]

CY1126036T1 - Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας - Google Patents

Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας

Info

Publication number
CY1126036T1
CY1126036T1 CY20231100265T CY231100265T CY1126036T1 CY 1126036 T1 CY1126036 T1 CY 1126036T1 CY 20231100265 T CY20231100265 T CY 20231100265T CY 231100265 T CY231100265 T CY 231100265T CY 1126036 T1 CY1126036 T1 CY 1126036T1
Authority
CY
Cyprus
Prior art keywords
sacubitril
valsartan
heart failure
dosage forms
therapeutic treatment
Prior art date
Application number
CY20231100265T
Other languages
English (en)
Inventor
Adel Redmond RIZKALA
Fabian CHEN
Victor Chengwei Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55967342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1126036(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1126036T1 publication Critical patent/CY1126036T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με δοσολογικά σχήματα σακουμπιτρίλης-βαλσαρτλανης για τη θεραπευτική αντιμετώπιση της καρδιακής ανεπάρκειας σε έναν ασθενή.
CY20231100265T 2015-05-11 2023-06-02 Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας CY1126036T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159703P 2015-05-11 2015-05-11
PCT/IB2016/052633 WO2016181284A1 (en) 2015-05-11 2016-05-09 Sacubitril-valsartan dosage regimen for treating heart failure

Publications (1)

Publication Number Publication Date
CY1126036T1 true CY1126036T1 (el) 2023-11-15

Family

ID=55967342

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100265T CY1126036T1 (el) 2015-05-11 2023-06-02 Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας

Country Status (15)

Country Link
US (2) US11058667B2 (el)
EP (3) EP3294283B1 (el)
JP (1) JP6576469B2 (el)
CY (1) CY1126036T1 (el)
DK (2) DK3294283T3 (el)
ES (2) ES3034658T3 (el)
FI (2) FI4212152T3 (el)
HR (2) HRP20250779T1 (el)
HU (2) HUE071910T2 (el)
LT (2) LT3294283T (el)
PL (2) PL4212152T3 (el)
PT (2) PT4212152T (el)
RS (2) RS66936B1 (el)
SI (2) SI4212152T1 (el)
WO (1) WO2016181284A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE071910T2 (hu) 2015-05-11 2025-10-28 Novartis Ag Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére
EP3117823A1 (en) * 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
US20210177803A1 (en) * 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
CN113286585B (zh) * 2019-09-20 2022-11-08 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
WO2021230664A1 (ko) * 2020-05-12 2021-11-18 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE60315795T2 (de) 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2939163T3 (es) 2007-11-06 2023-04-19 Novartis Ag Composiciones farmacéuticas basadas en superestructuras de antagonista/bloqueante del receptor de angiotensina (ARB) e inhibidor de la endopeptidasa neutra (NEP)
EP3943084A1 (en) * 2012-08-24 2022-01-26 Novartis AG Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
HUE071910T2 (hu) 2015-05-11 2025-10-28 Novartis Ag Szakubitril-valzartán adagolási rend krónikus szisztolés szívelégtelenség kezelésére

Also Published As

Publication number Publication date
HRP20250779T1 (hr) 2025-08-29
EP3294283A1 (en) 2018-03-21
FI4212152T3 (fi) 2025-07-11
RS66936B1 (sr) 2025-07-31
HUE071910T2 (hu) 2025-10-28
SI4212152T1 (sl) 2025-08-29
EP3294283B1 (en) 2023-03-08
PL4212152T3 (pl) 2025-08-11
WO2016181284A1 (en) 2016-11-17
US11058667B2 (en) 2021-07-13
SI3294283T1 (sl) 2023-07-31
LT3294283T (lt) 2023-06-12
US20220133694A1 (en) 2022-05-05
EP4212152A1 (en) 2023-07-19
ES3034658T3 (en) 2025-08-21
LT4212152T (lt) 2025-07-10
PT4212152T (pt) 2025-07-08
FI3294283T3 (fi) 2023-05-24
JP6576469B2 (ja) 2019-09-18
US20180125820A1 (en) 2018-05-10
RS64242B1 (sr) 2023-06-30
DK4212152T3 (da) 2025-06-23
EP4570314A2 (en) 2025-06-18
EP4570314A3 (en) 2025-09-10
HRP20230480T1 (hr) 2023-07-21
PL3294283T3 (pl) 2023-07-24
HUE062195T2 (hu) 2023-10-28
JP2018519266A (ja) 2018-07-19
DK3294283T3 (da) 2023-05-30
ES2945866T3 (es) 2023-07-10
PT3294283T (pt) 2023-06-07
EP4212152B1 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
CY1126036T1 (el) Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
KR102199943B9 (ko) 의료용 자극 장치
EP3399972A4 (en) LOW-DOSED THERAPEUTIC TREATMENT
DK3360508T3 (da) Hjælpeanordning til dental behandling
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
DK3612624T3 (da) Genterapi
EP3448263A4 (en) Electrotherapeutic treatment
EP3341074A4 (en) IMPLANTABLE STIMULATION ASSEMBLY
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
EP4125973A4 (en) Neoantigen vaccine therapy
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
EA201692534A1 (ru) Способы лечения гипотонии
HUE045409T2 (hu) Új PI3K gamma inhibitor peptid légzõszervi betegségek kezelésére
EP3455350A4 (en) PRIMO-VACCINATION / RECALL POLYTHERAPY